Axiom Investors LLC DE grew its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 274.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 86,600 shares of the company's stock after acquiring an additional 63,480 shares during the quarter. Axiom Investors LLC DE's holdings in Dr. Reddy's Laboratories were worth $1,367,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cerity Partners LLC increased its stake in Dr. Reddy's Laboratories by 69.6% during the third quarter. Cerity Partners LLC now owns 18,785 shares of the company's stock worth $1,492,000 after acquiring an additional 7,709 shares during the last quarter. Townsquare Capital LLC purchased a new position in shares of Dr. Reddy's Laboratories in the 3rd quarter worth approximately $286,000. Glenmede Trust Co. NA bought a new position in shares of Dr. Reddy's Laboratories during the 3rd quarter valued at approximately $207,000. Pinpoint Asset Management Ltd bought a new stake in Dr. Reddy's Laboratories in the third quarter worth $308,000. Finally, Quantinno Capital Management LP lifted its position in Dr. Reddy's Laboratories by 18.0% in the third quarter. Quantinno Capital Management LP now owns 20,237 shares of the company's stock worth $1,608,000 after buying an additional 3,094 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
RDY has been the topic of a number of analyst reports. StockNews.com cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. Nomura lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th.
View Our Latest Stock Analysis on RDY
Dr. Reddy's Laboratories Stock Up 0.7 %
Shares of RDY traded up $0.09 during mid-day trading on Wednesday, hitting $13.25. The company's stock had a trading volume of 1,364,777 shares, compared to its average volume of 1,327,829. The firm has a market capitalization of $11.06 billion, a price-to-earnings ratio of 21.10 and a beta of 0.48. Dr. Reddy's Laboratories Limited has a 52-week low of $12.50 and a 52-week high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company's 50-day moving average is $13.38 and its 200-day moving average is $14.55.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, equities research analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.
Dr. Reddy's Laboratories Profile
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Featured Stories
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
